GlaxoSmithKline
Global Health Outcomes, Vaccines
200 N. 16th Street
Philadelphia,
PA
USA
19102
Biographical Sketch:
2009-present Associate Director- US HEOR, Americas Health Services Center of Excellence BMS
As US HEOR lead for metabolic successfully launched the 2nd DPP IV in the US. Lead for all payer related activities (AMCP, BIM, CE) for the product, created 114 decks, Medicare Part D decks and other MCO economic presentation. Deliver a sound strategic post marketing HEOR activity plan for 2009-2011 that supports value story, brand strategy, and medical strategy. Support in Phase 4 clinical trails in identifying viable QOL and Economic end points. Lead for the CER activities related to the metabolic therapeutic area. In addition formulate, design, execute, and disseminate OR studies and modeling activities to support the unmet need, value story and brand strategy. Dedicated to working on the launch activities for the first in class SGLT-2 product under development. Work closely in a matrix organizational structure (medical, payer, Regulatory, compliance, legal, marketing), to ensure flawless execution of HEOR book of work and strategy that gains access and maintains access to the portfolio of the BMS metabolic profile.
2007-2009 Associate Director- Global Outcomes Research and Strategy
2006-present Associate Manager Global Outcomes Research and Health Technology Assessment- Merck & C0
Numerous publications with latest 2 cited
Maclean JR, Chapman RH, Ferrufino CP, Krishnarajah G. Drug titration patterns and HbA 1c levels in type 2 diabetes. Int J Clin Pract. 2009 Jul;63(7):1008-16
B Schwarz, M Gouveia, J Chen, G Nocea, K Jameson, J Cook, G Krishnarajah, E Alemao, D Yin, H Sintonen; Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes, obesity & metabolism, Vol. 10 Suppl 1 (June 2008), pp. 43-55.